Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cost of Revenue (2016)

Viridian Therapeutics, Inc.\DE has reported Cost of Revenue over the past 3 years, most recently at $692000.0 for Q4 2016.

  • Quarterly results put Cost of Revenue at $692000.0 for Q4 2016, up 51.75% from a year ago — trailing twelve months through Dec 2016 was $2.4 million (down 1.7% YoY), and the annual figure for FY2016 was $2.5 million, up 3.07%.
  • Cost of Revenue for Q4 2016 was $692000.0 at Viridian Therapeutics, Inc.\DE, up from $599000.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for VRDN hit a ceiling of $3.1 million in Q4 2014 and a floor of $66000.0 in Q2 2014.
  • Median Cost of Revenue over the past 3 years was $613500.0 (2016), compared with a mean of $744250.0.
  • Peak annual rise in Cost of Revenue hit 927.27% in 2015, while the deepest fall reached 85.12% in 2015.
  • Viridian Therapeutics, Inc.\DE's Cost of Revenue stood at $3.1 million in 2014, then tumbled by 85.12% to $456000.0 in 2015, then surged by 51.75% to $692000.0 in 2016.
  • The last three reported values for Cost of Revenue were $692000.0 (Q4 2016), $599000.0 (Q3 2016), and $628000.0 (Q2 2016) per Business Quant data.